Related Experiment Video
Updated: Jun 24, 2026

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Therapeutic options for metastatic breast cancer
Patrick G Morris1, Heather L McArthur, Clifford A Hudis
1Memorial Sloan-Kettering Cancer Center, Breast Cancer Medicine Service, NY 10065, New York, USA.
Abstract:
Metastatic breast cancer (MBC) remains an incurable disease despite ongoing therapeutic advances. Recently there has been progress extending the range of available cytotoxic chemotherapy drugs and optimizing their scheduling. In addition, a greater understanding of tumor biology has led to the development of a number of targeted therapies. Several of these newer agents, such as trastuzumab, lapatinib and bevacizumab, have demonstrated activity in combination with chemotherapy and have improved the prognosis of patients with MBC. We hope that further progress elucidating the pathophysiology and biology of MBC will continue to lead to corresponding advances in treatment.
Insights
Metastatic breast cancer (MBC) treatment advances include new chemotherapy schedules and targeted therapies like trastuzumab. These improve outcomes for MBC patients, with ongoing research promising further breakthroughs.
Area of Science:
- Oncology
- Medical Research
Background:
- Metastatic breast cancer (MBC) is currently incurable.
- Therapeutic strategies for MBC are evolving.
- Advances in understanding tumor biology are crucial.
Purpose of the Study:
- To review recent advances in the treatment of metastatic breast cancer.
- To highlight the role of chemotherapy and targeted therapies.
- To discuss the impact of these advances on patient prognosis.
Main Methods:
- Review of current literature on MBC treatment.
- Analysis of the efficacy of novel chemotherapeutic agents and targeted therapies.
- Evaluation of combination treatment strategies.
Main Results:
- Chemotherapy drug selection and scheduling have improved.
- Targeted therapies (trastuzumab, lapatinib, bevacizumab) show activity in MBC.
- Combination therapies with chemotherapy have enhanced patient prognosis.
Conclusions:
- Ongoing research into MBC pathophysiology and biology is essential.
- Further therapeutic advances are anticipated.
- Improved understanding will continue to drive treatment innovation.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Tumor Immunotherapy

